Latest From Cerecin Inc.
The US bioventure Accera, hit by a Phase III failure for its lead candidate last year, is expanding into Asia and renaming itself as it remains hopeful of progressing its core investigational asset in a targeted population of Alzheimer’s disease patients.
E-Scape's Series A cash will fund the development of small molecules targeting genetic drivers of neurodegenerative diseases, such as ApoE4 in Alzheimer's disease. The venture capital financing with big pharma backing will be used to take two programs into the clinic.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
- Therapeutic Areas
- Neurology, Nervous System
- Accera Inc.
- Southeast Asia
- Parent & Subsidiaries
- Cerecin Inc.
- Senior Management
Charles Stacey, MD, Pres. & CEO
Samuel Henderson, PhD, CSO
Jerris Knaisch, VP, Fin. & North American Operations
Cheryl Tan, BSc, VP, Commercial & Partnering
Judy Walker, MD, CMO
- Contact Info
Phone: 6813 2999
8 Shenton Way, #08-02
, CO 06881
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.